Brief: OmniAb Enters In Technology License And Services Agreement For Antibody Discovery With A Newly-Formed Incubated Company Of Arrowmark Partners And Viking Global Investors
17/11/2025 22:36
Nov 17 (Reuters) - OmniAb Inc OABI.O: OMNIAB ENTERS INTO A TECHNOLOGY LICENSE AND SERVICES AGREEMENT FOR ANTIBODY DISCOVERY WITH A NEWLY-FORMED INCUBATED COMPANY OF ARROWMARK PARTNERS AND VIKING GLOBAL INVESTORS OMNIAB INC - TO RECEIVE REVENUE FOR SERVICES, EQUITY, AND ROYALTIES UNDER AGREEMENT Source text: ID:nBw5WrRGZa Further company coverage: OABI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on OmniAB
See all newsU.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
OmniAb rises on drug discovery deal with Lilly worth up to $370 million
U.S. STOCKS ON THE MOVE - KBR, Vista Energy, Fulcrum Therapeutics
OmniAb rises on drug discovery deal with Lilly worth up to $370 mln